TaiMed Biologics Inc (中裕新藥) expects quarterly sales to grow this year as a distribution partner expands prescription reimbursement coverage for Trogarzo, its newly approved HIV/AIDS drug.
Since gaining approval from the US Food and Drug Administration in March and commencing sales in the US on April 30, Trogarzo’s commercialization has been progressing at pace similar to that of previous new HIV/AIDS drug launches, TaiMed chief financial officer Jack Chen (陳怡成) yesterday told an investors’ conference in Taipei.
Montreal-based Theratechnologies Inc, TaiMed’s marketing and distribution partner in the US and Canada, is expected to finish negotiations with major public and private health insurance firms in the next four to six months, he said.
Based on precedents set by 13 other antiretroviral drugs, Trogarzo sales are expected to peak in its fourth year in that market, Chen said.
The US is the world’s biggest market for HIV/AIDS treatments, with about 1.4 million people infected, of which 450,000 to 650,000 are receiving treatment and an estimated 200,000 to 250,000 have developed multidrug resistance, he said.
TaiMed is looking to tap into the demand from an estimated 10,000 to 12,000 patients with multidrug resistance who are in need of alternative treatment options, such as Trogarzo, he added.
The company this year adopted the International Financial Reporting Standards 9 guidelines, marking a switch from the International Accounting Standards 18 it had been using until the end of last year, Chen said.
The change in accounting rules would affect the recognition of earnings from milestone payments and the valuation of 2.3 million Theratechnologies shares TaiMed received as part of its partnership with the Canadian firm, he said.
“We expect continued revisions to international accounting standards and are ready to make adjustments,” Chen said.
“It is better to track the company’s operating performance on a quarterly basis, as monthly sales could fluctuate widely due to time lag,” he said, adding that Trogarzo is produced by a manufacturing partner in China and product shipments to packaging and logistics centers in the US are based on anticipated demand.
The company’s NT$1 billion (US$33.4 million) plant in Hsinchu County’s Jhubei City (竹北) is expected to come online in 2020, which would help diversify production and cut reliance on WuXi Biologics (無錫生物製藥), a Chinese contract manufacturer, he said.
Inhouse manufacturing is expected to bring cost savings of 20 percent to 40 percent, he added.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure